ROVI updates its strategy in a meeting with shareholders, investors and analysts
Mié, 23/11/2022 - 00:00
1 minROVI updates its strategy in a meeting with shareholders, investors and analysts
Relacionados
ROVI informa sobre el proceso de evaluación para la obtención de la autorización de comercialización en Estados Unidos de Risvan®
La...
1 min
28/07/2023
Al cierre del primer semestre de 2023
ROVI ALCANZA UNOS INGRESOS DE 381 MILLONES DE EUROS EN EL PRIMER SEMESTRE POSPANDEMIA
La...
20 min
26/07/2023
Crecimiento histórico y gran apuesta por la Investigación
ROVI incrementa un 26% los ingresos operativos y un 30% el beneficio neto en...
11 min
14/06/2023
6s3a6968_1.jpg
TO THE SPANISH NATIONAL SECURITIES MARKET COMMISSION
(COMISIÓN NACIONAL DEL MERCADO DE VALORES)
Madrid, 23 November 2022
In compliance with the reporting requirements provided for in article 227 of the consolidated text of the Securities Market Act, ROVI sends and publishes the attached presentation regarding the update of the company strategy, a presentation that will be distributed today and which can be accessed through the website of the company. Likewise, ROVI will hold an in-person and virtual meeting today with analysts and investors to present said presentation.
Mr. Juan López-Belmonte Encina
Chairman and Chief Executive Officer
Laboratorios Farmacéuticos ROVI, S.A.